Company Filing History:
2 out of 531 
1 out of 67 Years Active: 2007-2010
Title: The Innovations of Francoise Denamur
Introduction
Francoise Denamur is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of virology, particularly in the development of vaccines for rotavirus. With a total of three patents to his name, Denamur's work has the potential to impact public health positively.
Latest Patents
Denamur's latest patents include a homogeneous attenuated human rotavirus population. This invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. Additionally, he has developed an immunogenic composition of a homogeneous live attenuated human rotavirus population, which also includes the same characteristics and formulation for a rotavirus vaccine in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.
Career Highlights
Throughout his career, Denamur has worked with prominent companies in the pharmaceutical industry, including GlaxoSmithKline Biologicals SA and SmithKline Beecham Biologicals SA. His experience in these organizations has contributed to his expertise in vaccine development and virology.
Collaborations
Some of his notable coworkers include Brigitte Desiree Alberte Colau and Isabelle Knott. Their collaboration has likely enriched the research environment and fostered innovative solutions in their field.
Conclusion
Francoise Denamur's contributions to vaccine development and virology through his patents and collaborations highlight his importance in the scientific community. His work continues to pave the way for advancements in public health.